%{search_type} search results

2,871 catalog results

RSS feed for this result
Software/Multimedia
1 online resource (391 p.) : ill. (some col.)
"With the alarming increase in cancer diagnoses and genetic illnesses, traditional drug agents and their delivery media need to be re-evaluated to address a quickly evolving field. With newer smart materials for the controlled release of macromolecules, peptides, genetic material, etc. further complications arise, such as material performance, synthesis, functionalization and targeting, biological identity, and biocompatibility. The book provides a comprehensive overview of the recent developments on "smart" targeting and drug delivery systems with a variety of carriers like nanoparticles, membranes, and hydrogels. It contains detailed descriptions on the recent trends in this field in the ongoing battle with catastrophic diseases like cancer. This field of research has been in its infancy and continues to face growth, and with it, further challenges and difficulties along the way toward maturity, which are accurately introduced in this book."-- Provided by publisher.
Book
1 online resource.
Book
xlii, 546 pages : illustrations (some color) ; 25 cm.
"Volume 18, entitled Metallo-Drugs: Development and Action of Anticancer Agents of the series Metal Ions in Life Sciences centers on biological, medicinal inorganic chemistry. The serendipitous discovery of the antitumor activity of cis-diamminodichloroplatinum(II) (cisplatin) by Barnett Rosenberg in the 1960s is a landmark in metallodrug-based chemotherapy. The success of cisplatin in the clinic, followed by oxaliplatin and carboplatin, along with their drawbacks relating mainly to resistance development and severe toxicity, initiated research on polynuclear platinum complexes and on Pt(IV) complexes as prodrugs. Furthermore, the indicated shortcomings led to the exploration of other transition and main group metal ions, among them Ru(II/III), Au(I/III), Ti(IV), V(IV/V), and Ga(III) including also the essential metal ions Fe(II/III), Cu(I/II), and Zn(II). Ionic as well as covalent and non-covalent interactions between structurally very different complexes and biomolecules like nucleic acids, proteins, and carbohydrates are studied and discussed with regard to their possible anticancer actions. Hence, MILS-18 summarizes the research at the forefront of medicinal inorganic chemistry, including studies on the next-generation, tailor-made anticancer drugs. All this and more is treated in an authoritative and timely manner in the 17 stimulating chapters of this book, written by 39 internationally recognized experts from 10 nations (from the US via Europe to China and Australia). The impact of this vibrant research area is manifested by more than 2700 references, nearly 150 illustrations (more than half in color) and several comprehensive tables. Metallo-Drugs: Development and Action of Anticancer Agents is an essential resource for scientists working in the wide range from enzymology, material sciences, analytical, organic, and inorganic biochemistry all the way through to medicine including the clinic ... not forgetting that it also provides excellent information for teaching"--Provided by publisher.
Science Library (Li and Ma)
Book
1 online resource.
  • 1. Introduction of Mid-Size Drugs and Peptidomimetics.- 2. Chloroalkene Dipeptide Isosteres as Peptidomimetics.- 3. Conformational-restricted Cyclic Peptides.- 4. Peptidomimetics that Mimic Secondary Structures of Peptides.- 5.Peptidomimetics that Mimic Tertiary Structures of Peptides.- 6. Conjugated Compounds Involving Peptides.- 7. Summary and Future Perspectives of Researches on Mid-Size Drugs.
  • (source: Nielsen Book Data)9789811076909 20180430
This brief describes studies conducted by the authors on mid-size drugs utilizing peptides and peptidomimetics, and on the development of anti-HIV agents. Peptides are important biological molecules and have various physiological actions. Peptide-based drug discovery may help bring about the development of useful medicines that are highly safe and show potent pharmacological effects in small doses. Recently, it has been shown that there is an important drug-like space in the mid-sized region between low- and high-molecular-weight compounds. Thus, mid-size drugs such as peptide compounds are being focused on. To date, several peptidomimetics that mimic primary, secondary, and tertiary structures of peptides have been developed to maintain and improve biological activities and actions of peptides. In this book, the features and advantages of mid-size drugs are described in detail. In addition, the merits of utilizing peptidomimetics in the development of mid-size drugs are referred to. Understanding such peptide-derived mid-size drugs will lead to a comprehensive expansion of medicinal chemistry.
(source: Nielsen Book Data)9789811076909 20180430
Book
pages ; [ca. 23-29] cm
  • Pharmacotherapy, Toxicodynamics and Regulatory Science-Divergent Objectives Nonclinical Pharmacokinetics - a primer Routes - with considerations for species specificity Delivery Systems Regimens Fundamentals of Nonclinical Formulation Excipients and Vehicles: Tolerance and toxicity Appendices.
  • (source: Nielsen Book Data)9781466502536 20171218
If we will ever achieve Paul Ehrlich's "magic bullet, " that is, a molecule which goes with high selectivity to the therapeutic target site, does what it needs to do, and is subsequently cleared from the body, the practice of safety assessment will have to change. Nonclinical Drug Administration: Formulations, Routes and Regimens for Solving Drug Delivery Problems in Animal Model Systems seeks to address a trio of objectives that, though separate, are linked and central to biomedical science and, ultimately, medicine. Rather seeing these as separate "silos, " those working in nonclinical safety assessment will have to view these three in an integrated manner and to regularly and thoughtfully incorporate new information and technology. The trio of objectives this book explores are: first, to present how to deliver more of a drug product systemically to facilitate the regulatory need for evaluating safety and efficacy in animal species (at elevated exposure levels) prior to advancing the drug to human testing; second is to achieve better tolerance to therapeutics administration in test animals and humans which achieves objectives 1 and 3; and third, to explore ways to improve on therapeutic target receptor delivery performance, therefore improving both clinical pharmacodynamics bioavailability and specificity. The book's ten chapters assemble the basic concepts, principles and hypotheses involved in quantitative receptor and chronological organism interaction dynamics central to the successful development of new therapeutics which depend on systemic administration to achieve desired therapeutic goals and in so doing avoid outcomes which limit, marginalize, or preclude the therapeutic use of so many molecules.
(source: Nielsen Book Data)9781466502536 20171218
The concept of the perfect medicine as a molecule that goes with high selectivity to the therapeutic target site, does what it needs to do, and is subsequently cleared from the body is especially relevant now. Much of the current costs and post-market safety concerns arise from the inability to achieve adequate concentrations and selectivity in the due course of actually delivering the active drug. Providing an integrated approach, this book presents ways of achieving the desired adequate and selective delivery using the currently available technology in three tool sets: route, regimen, and formulation.
(source: Nielsen Book Data)9781466502598 20171218
Book
200 pages : color illustrations, color maps, charts ; 24 cm
  • Dédicaces et remerciements -- Préface -- Avant-propos -- Contexte biogéographique -- Les difficultés et contraintes de la gestion des plantes médicinales -- Situation de l'étude -- Le degré d'alerte -- L'environnement social -- Le potentiel de la biodiversité du Sénégal -- Méthodologie -- Résultats -- Intérêt et limites de l'étude -- La diversité culturelle est la base de la diversité biologique -- Les savoirs locaux -- Quelle valeur donner aux savoirs locaux pour une gestion durable des plantes médicinales ? -- Caractérisation des tradipraticiens -- Pathologies -- Périodes de récolte -- Techniques de coupe, de conditionnement et les mesures conservatoires préconisées pour une gestion durable des plantes médicinales -- La Formation des acteurs -- La mise en place d'un cadre de collaboration entre les associations des herboristes, des tradipraticiens, des ONG et la DEFCCS -- Quantités de plantes médicinales exploitées durant les quatre dernières années (2005 à 2008) -- Valorisation des plantes médicinales par une politique d'harmonisation du contrôle de la commercialisation -- Recommandations -- Conclusion -- Liste de quelques plantes médicinales ayant complètement disparu dans huit régions du Sénégal -- Liste des acronymes -- Bibliographie -- Note sur l'auteur.
"Cet ouvrage est le fruit de trente-trois années de recherche sur les plantes médicinales et les savoirs locaux. Colonel Papa Momar Faye nous y invite à mieux connaître les plantes médicinales récoltées par les herboristes et leur degré de protection. On y retrouve également une cartographie des sites des tradipraticiens sérieux et compétents. Cet ouvrage permet par ailleurs d'alerter sur les menaces qui pèsent sur les plantes médicinales et de sensibiliser les autorités, les bailleurs sur les pressions subies par les plantes médicinales. Enfin l'auteur propose des solutions pour une meilleure conservation et gestion de ces ressources."--Page 4 of cover.
Green Library
Book
1 online resource.
Social and Administrative Aspects of Pharmacy in Low- and Middle-Income Countries: Present Challenges and Future Solutions examines the particularities of low- and middle-income countries and offers solutions based on their needs, culture and available resources. Drawing from the firsthand experience of researchers and practitioners working in these countries, this book addresses the socio-behavioral aspects of pharmacy and health, pharmacoeconomics, pharmaceutical policy, supply management and marketing, pharmacoepidemiology and public health pharmacy specific to low- and middle-income countries. While some practices may be applied appropriately in disparate places, too often pharmacy practice in low- and middle-income countries is directly copied from successes in developed countries, despite the unique needs and challenges low- and middle-income countries face.
Book
1 online resource.
  • 1. Significance of medicinal plants in human life 2. Drug synthesis from natural products: A historical overview and future perspective 3. Substituting medicinal plants through drug synthesis 4. Bioactive Constituents of Neem 5. Turmeric: Isolation and synthesis of important biological molecules 6. Properties and important molecules of medicinal interest in wood apple (Aegle marmelos) 7. Medicinally important constituents of Tulsi (Ocimum spp.) 8. Biological importance of Aloe vera and its active constituents 9. Alkaloid group of Cinchona officinalis: Structural, synthetic and medicinal aspects 10. Isolation of medicinally important constituents from rare and exotic medicinal plants 11. Medicinal properties of marine plants 12. Ayurveda: A new dimension in the era of modern medicine 13. Dual role of drugs: Beneficial and harmful aspects 14. Introduction to medicinally important constituents from Chinese medicinal plants.
  • (source: Nielsen Book Data)9780081020715 20180611
Synthesis of Medicinal Agents from Plants highlights the importance of synthesizing medicinal agents from plants and outlines methods for performing it effectively. Beginning with an introduction to the significance of medicinal plants, the book goes on to provide a historical overview of drug synthesis before exploring how this can be used to successfully replicate and adapt the active agents from natural sources. Chapters then explore the medicinal properties of a number of important plants, before concluding with a discussion of the future of drugs from medicinal plants. Illustrated with real-world examples, it is a practical resource for researchers in this field. In an age of rapid environmental destruction, hundreds of medicinal plants are at risk of extinction from overexploitation and deforestation, limiting the natural resources available for active agent extraction, thereby threatening the discovery of future cures for diseases. Simultaneously, with the increasing population and advances in medical sciences, the demand for drugs is continuously increasing and cannot be met with just plants. The ability to synthetically replicate the active compounds from these plants is essential in creating an ecologically-aware, sustainable future for drug design.
(source: Nielsen Book Data)9780081020715 20180611
Book
1 online resource (xvi, 294 pages) : illustrations (some color). Digital: text file; PDF.
  • Optocapacitance allows for photostimulation of neurons without requiring genetic modification / Joao L. Carvalho-de-Souza, Jeremy S. Treger, David R. Pepperberg, and Francisco Bezanilla
  • Nanoparticle-assisted localized optical stimulation of cultured neurons / Flavie Lavoie-Cardinal, Charleen Salesse, Pierre-Luc Ayotte-Nadeau, and Paul De Koninck
  • Stimulation of primary auditory neurons mediated by near-infrared excitation of gold nanorods / Chiara Paviolo, Karina Needham, William G.A. Brown, Jiawey Yong, and Paul R. Stoddart
  • Nanoparticle preparation for magnetothermal genetic stimulation in cell culture and in the brain of live rodents / Idoia Castellanos-Rubio, Rahul Munshi, Shahnaz Qadri, and Arnd Pralle
  • Genetically encoded nanoparticles for neural modulation / Sarah A. Stanley
  • Two applications of gold nanostars to hippocampal neuronal cells : localized photothermal ablation and stimulation of firing rate / Fidel Santamaria and Xomalin G. Peralta
  • Regulating growth cone motility and axon growth by manipulating targeted superparamagnetic nanoparticles / Tanchen Ren, Jeffrey L. Goldberg, and Michael B. Steketee
  • Assessment of the effects of a wireless neural stimulation mediated by piezoelectric nanoparticles / Attilio Marino, Satoshi Arai, Yanyan Hou, Mario Pellegrino, Barbara Mazzolai, Virgilio Mattoli, Madoka Suzuki, and Gianni Ciofani
  • Influence of external electrical stimulation on cellular uptake of gold nanoparticles / Samantha K. Franklin, Brandy Vincent, Sumeyra Tek, and Kelly L. Nash
  • Estimating the effects of nanoparticles on neuronal field potentials based on their effects on single neurons in vitro / Michael Busse, Narsis Salafzoon, Annette Kraegeloh, David R. Stevens, and Daniel J. Strauss
  • Application of in vivo extracellular recording technique to study the biological effects of nanoparticles in brain / Yanyan Miao, Han Zhao, Jutao Chen, Ming Wang, and Longping Wen
  • Using the whole cell patch clamp technique to study the effect of nanoparticles in hippocampal neurons / Xiaochen Zhang and Zhuo Yang
  • Comparative analysis of neurotoxic potential of synthesized, native, and physiological nanoparticles / Arsenii Borysov, Natalia Pozdnyakova, Artem Pastukhov, and Tatiana Borisova
  • Stoichiometrically defined neural coculture model to screen nanoparticles for neurological applications / Stuart I. Jenkins and Divya M. Chari
  • Long-term organism distribution of microwave hydrothermally synthesized ZrO2 : Pr nanoparticles / Jarosław Kaszewski, Paula Kiełbik, Anna Słońska-Zielonka, Izabela Serafińska, Jakub Nojszewski, Marek Godlewski, Zdzisław Gajewski, and Michał M. Godlewski
  • Gold nanoparticles as nucleation centers for amyloid fibrillation / Yanina D. Álvarez, Jesica V. Pellegrotti, and Fernando D. Stefani.
This volume discusses techniques to synthesize and functionalize nanoparticles, monitor their delivery and uptake, and identify and evaluate their lethal and non-lethal effects on the metabolic activity of the nervous system. The chapters in this book are divided into 4 sections: photo-stimulation, thermal stimulation, mechanical perturbation, and toxicity and physiological effects. The first 3 sections focus on nanoparticle interactions with external sources that disturb the neuronal system, while the 4th explores the effects of having nanoparticles in a neuronal system in the absence of external stimuli. In Neuromethods series style, chapters include the kind of detail and key advice from the specialists needed to get successful results in your laboratory. Cutting-edge and comprehensive, Use of Nanoparticles in Neuroscience is a valuable resource for graduate students and specialized researchers that want to learn techniques needed to quantify experiments that use nanoparticles in the nervous system.
(source: Nielsen Book Data)9781493975822 20180312
Book
1 online resource.
  • List of Contributors xvii Preface xxi Historical Perspective: What Makes Antibody Drug Conjugates Revolutionary? xxiii Part I What is an Antibody Drug Conjugate 1 1 Typical Antibody Drug Conjugates 3 John M. Lambert 1.1 Introduction 3 1.2 The Building Blocks of a Typical ADC 6 1.3 Building an ADC Molecule 13 1.4 Attributes of a Typical ADC 19 1.5 Summary 24 Acknowledgment 24 Abbreviations 25 References 25 Part II Engineering, Manufacturing, and Optimizing Antibody Drug Conjugates 33 2 Selecting Optimal Antibody Drug Conjugate Targets Using Indication-Dependent or Indication-Independent Approaches 35 Jay Harper and Robert Hollingsworth 2.1 Characteristics of an Optimal ADC Target 35 2.2 Indication-Dependent ADC Target Selection 40 2.3 Indication-Independent ADC Target Selection 48 2.4 Concluding Remarks and Future Directions 50 Acknowledgments 52 References 52 3 Antibody Drug Conjugates: An Overview of the CMC and Characterization Process 59 Philip L. Ross and Janet Wolfe 3.1 Introduction 59 3.2 ADC Manufacturing Process 60 3.3 Characterization 70 3.4 Comparability 76 3.5 Concluding Remarks 76 Abbreviations 77 References 78 4 Linker and Conjugation Technology-- and Improvements 85 Riley Ennis and Sourav Sinha 4.1 Overview 85 4.2 Noncleavable 86 4.3 Cleavable Linkers and Self -Immolative Groups 86 4.4 Differences in Therapeutic Window of Cleavable and Noncleavable Linkers 88 4.5 Improving Therapeutic Window with Next -Generation Linker Technologies 89 4.6 Site -Specific Conjugation, Homogeneous Drug Species, and Therapeutic Window 91 4.7 Influence of Linkers on Pharmacokinetics and ADME 93 4.8 PEG Linkers to Optimize Clearance, Solubility, and Potency 93 4.9 Linkers to Optimize for Drug Resistance 94 4.10 Improving Solid Tumor Penetration with Linkers 96 4.11 Analytical Methods for Characterizing Linker Pharmacodynamics 96 4.12 Conclusion 98 References 99 5 Formulation and Stability 105 Kouhei Tsumoto, Anthony Young, and Satoshi Ohtake 5.1 Introduction 105 5.2 Stability Considerations for ADCs 106 5.3 Formulation Approaches 115 5.4 Logistical Considerations 123 5.5 Summary and Close 125 References 126 6 QC Assay Development 131 Xiao Hong. Chen and Mate Tolnay 6.1 Introduction 131 6.2 Drug -to -Antibody Ratio 132 6.3 Drug Loading Distribution 133 6.4 Positional Isomers 136 6.5 ADC Concentration 136 6.6 Drug -Related Substances 137 6.7 Antigen Binding Assays and Potential Impact of Drug Conjugation 137 6.8 Cell -Based Cytotoxicity Assays 139 6.9 Assays to Monitor Fc -Dependent Effector Functions to Characterize Additional Possible Mechanisms of Action 140 6.10 Immunogenicity Assays to Monitor the Immune Response to ADC 142 6.11 Conclusions 144 6.12 Key Guidance Documents 145 Acknowledgments 145 References 145 7 Occupational Health and Safety Aspects of ADCs and Their Toxic Payloads 151 Robert Sussman and John Farris 7.1 Introduction 151 7.2 Background on ADCs 152 7.3 Occupational Hazard Assessment of ADCs and Their Components 157 7.4 Occupational Implications and Uncertainties 159 7.5 General Guidance for Material Handling 160 7.6 Facility Features and Engineering Controls 163 7.7 Specific Operational Guidance 165 7.8 Personal Protective Equipment 167 7.9 Training 168 7.10 Industrial Hygiene Monitoring 169 7.11 Medical Surveillance Program 171 7.12 Summary and Future Direction 172 References 172 Part III Nonclinical Approaches 177 8 Bioanalytical Strategies Enabling Successful ADC Translation 179 Xiaogang Han, Steven Hansel, and Lindsay King 8.1 Introduction 179 8.2 ADC LC/MS Bioanalytical Strategies 182 8.3 Non -Regulated ADC Pharmacokinetic and Immunogenicity Support Using Ligand Binding Assays 190 8.4 Biodistribution Assessment 195 8.5 Regulated ADC Pharmacokinetics and Immunogenicity Evaluation 196 8.6 ADC Biomeasures and Biomarkers 199 8.7 Summary 200 References 201 9 Nonclinical Pharmacology and Mechanistic Modeling of Antibody Drug Conjugates in Support of Human Clinical Trials 207 Brian J. Schmidt, Chin Pan, Heather E. Vezina, Huadong Sun, Douglas D. Leipold, and Manish Gupta 9.1 Introduction 207 9.2 Cell Line Testing 210 9.3 Xenograft Models 214 9.4 Nonclinical Testing to Support Investigational New Drug Applications 216 9.5 Mechanistic Modeling of Antibody Drug Conjugates 220 9.6 Target -Mediated Toxicity of Antibody Drug Conjugates 228 9.7 Considerations for Nonclinical Testing Beyond Antibody Drug Conjugate Monotherapies 229 9.8 Summary 230 Acknowledgments 231 References 231 10 Pharmacokinetics of Antibody Drug Conjugates 245 Amrita V. Kamath 10.1 Introduction 245 10.2 Pharmacokinetic Characteristics of an ADC 246 10.3 Unique Considerations for ADC Pharmacokinetics 250 10.4 Tools to Characterize ADC PK/ADME 254 10.5 Utilization of ADC Pharmacokinetics to Optimize Design 257 10.6 Pharmacokinetics of Selected ADCs 259 10.7 Summary 261 References 262 11 Path to Market Approval: Regulatory Perspective of ADC Nonclinical Safety Assessments 267 M. Stacey Ricci, R. Angelo De Claro, and Natalie E. Simpson 11.1 Introduction 267 11.2 FDA Experience with ADCs 268 11.3 Regulatory Perspective of the Nonclinical Safety Assessment of ADCs 269 11.4 Concluding Remarks 282 References 283 Part IV Clinical Development and Current Status of Antibody Drug Conjugates 285 12 Antibody Drug Conjugates: Clinical Strategies and Applications 287 Heather E. Vezina, Lucy Lee, Brian J. Schmidt, and Manish Gupta 12.1 Antibody Drug Conjugates in Clinical Development 287 12.2 Therapeutic Indications 291 12.3 Transitioning from Discovery to Early Clinical Development 292 12.4 Challenges and Considerations in the Design of Phase 1 Studies 293 12.5 First-in-Human Starting Dose Estimation 293 12.6 Dosing Strategy Considerations 294 12.7 Dosing Regimen Optimization 295 12.8 Phase 1 Study Design 297 12.9 Supportive Strategies for Phase 1 and Beyond 299 12.10 Clinical Pharmacology Considerations 301 12.11 Organ Impairment Assessments 301 12.12 Drug Drug Interaction Assessments 302 12.13 Immunogenicity 303 12.14 QT/QTc Assessments 303 12.15 Pharmacometric Strategies 307 12.16 Using Physiologically Based Pharmacokinetic and Quantitative Systems Pharmacology Models with Clinical Data 308 12.17 Summary and Conclusions 311 Acknowledgments 311 References 311 13 Antibody Drug Conjugates (ADCs) in Clinical Development 321 Joseph McLaughlin and Patricia LoRusso 13.1 Introduction and Rationale 321 13.2 Components of ADCs in Development 321 13.3 Landscape of ADCs 329 13.4 Clinical Use of ADCs 330 13.5 Future of ADCs 330 13.6 ADCs in Development 330 13.7 Future Directions 340 References 340 14 ADCs Approved for Use: Trastuzumab Emtansine (Kadcyla(R), T-DM1) in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer 345 Gail D. Lewis Phillips, Sanne de Haas, Sandhya Girish, and Ellie Guardino 14.1 Introduction 345 14.2 Preclinical Development of T-DM1 348 14.3 Early Clinical Studies of T-DM1 357 14.4 Clinical Pharmacology and Pharmacokinetics 361 14.5 Phase III Studies of T-DM1 in Patients with HER2-Positive MBC 362 14.6 Future Directions 371 14.7 Summary 373 References 374 15 ADCs Approved for Use: Brentuximab Vedotin 381 Monica Mead and Sven de Vos 15.1 Introduction 381 15.2 Early Efforts to Target CD30 with Monoclonal Antibodies 383 15.3 BV: Preclinical Data 386 15.4 Clinical Context 394 15.5 Mechanisms of Resistance 395 15.6 Current Research 397 15.7 Discussion 400 References 401 16 Radioimmunotherapy 409 Savita V. Dandapani and Jeffrey Wong 16.1 History of Radioimmunotherapy 409 16.2 Radioisotopes 410 16.3 Chemistry of RIT 411 16.4 Radioimmunotherapy Antibody Targets in Use Today (Table 16.2) 412 16.5. Other Hematologic Targets 415 16.6 Solid Tumors 417 16.7 Combination Therapy with RIT: Chemotherapy and/or Radiation 420 16.8 RIT and External Beam Radiation Treatment (EBRT) 421 16.9 RIT and EBRT and Chemotherapy 421 16.10 RIT Administration 422 16.11 Future of RIT 422 References 423 Part V Future Perspectives in Antibody Drug Conjugate Development 431 17 Radiolabeled Antibody -Based Imaging in Clinical Oncology 433 Bart S. Hendriks and Daniel F. Gaddy 17.1 Introduction 433 17.2 Applications for Clinical Antibody Imaging 434 17.3 Antibodies as Imaging Agents 435 17.4 Nuclear Imaging Gamma Camera (Planar) Scintigraphy and SPECT 439 17.5 Nuclear Imaging - PET 448 17.6 Commercialization Considerations 456 17.7 Summary 461 References 462 18 Next-Generation Antibody Drug Conjugate Technologies 473 Amy Q. Han and William C. Olson 18.1 Introduction 473 18.2 Novel Cytotoxic Payloads and Linkers 474 18.3 Tailoring Antibodies for Use as ADCs 482 18.4 Conclusions 491 References 491 Index 505.
  • (source: Nielsen Book Data)9781119060680 20170313
Providing practical and proven solutions for antibody-drug conjugate (ADC) drug discovery success in oncology, this book helps readers improve the drug safety and therapeutic efficacy of ADCs to kill targeted tumor cells. Discusses the basics, drug delivery strategies, pharmacology and toxicology, and regulatory approval strategies Covers the conduct and design of oncology clinical trials and the use of ADCs for tumor imaging Includes case studies of ADCs in oncology drug development Features contributions from highly-regarded experts on the frontlines of ADC research and development.
(source: Nielsen Book Data)9781119060680 20170313
Book
1 online resource (xvii, 291 pages)
  • List of Contributors 1. IntroductionDonald Huddler 2. Thermodynamics in Drug DiscoveryOBrienMarkova&Holdgate 3. Tailoring Hit Identification and Qualification Methods for Targeting Protein-Protein InteractionsBjorn Walse, Andrew P. Turnbull, Susan M. Boyd 4. HYDROGEN DEUTERIUM EXCHANGE MASS SPECTROMETRY IN DRUG DISCOVERYThorleif Lavold, Roman Zubarev and Juan Astorga-Wells 5. MICROSCALE THERMOPHORESIS IN DRUG DISCOVERYTanja Bartoschik, Melanie Maschberger, Alessandra Feoli, Timon Andre, Philipp Baaske, Stefan Duhr and Dennis Breitsprecher 6. SPR Screening Applying the new generation of SPR hardwareKartik Narayan and Steve Carroll 7. Weak Affinity Chromatography (WAC)Sten Ohlsonâ and Minh-Dao Duong-Thi 8. 1D NMR Methods for Hit IdentificationMary J Harner, Guille Metzler, Caroline A Fanslau, Luciano Mueller, William J Metzler 9. Protein-Based NMR Methods Applied to Drug DiscoveryAlessio Bortoluzzi, Alessio Ciulli 10. Applications of Ligand and Protein-observed NMR in DiscoveryIsabelle Krimm Conclusion 11. Using Biophysical Methods to Optimize Compound Residence TimeG. A. Holdgate, P. Rawlins, M. Bista, C. J. Stubbs 12. Applying biophysical and biochemical methods to the discovery of allosteric modulators of the AAA ATPase p97Stacie L. Bulfer and Michelle R. Arkin 13. Driving Drug Discovery with Biophysical Information Application to Staphylococcus aureus Dihydrofolate Reductase (DHFR)Parag Sahasrabudhe, Veerabahu Shanmugasundaram, Mark Flanagan, Kris A. Borzilleri, Holly Heaslet, Anil Rane, Alex McColl, Tim Subashi, George Karam, Ron Sarver, Melissa Harris, Boris A. Chrunyk, Chakrapani Subramanyam, Thomas V. Magee, Kelly Fahnoe, Brian Lacey, Henry Putz, J. Richard Miller, Jaehyun Cho, Arthur Palmer III and Jane M. Withka 14. Assembly of fragment screening libraries: Property and diversity analysisBradley C. Doak, Craig J. Morton, Jamie S. Simpson & Martin J. Scanlon Index.
  • (source: Nielsen Book Data)9781119099482 20170731
Applied Biophysics for Drug Discovery is a guide to new techniques and approaches to identifying and characterizing small molecules in early drug discovery. Biophysical methods are reasserting their utility in drug discovery and through a combination of the rise of fragment-based drug discovery and an increased focus on more nuanced characterisation of small molecule binding, these methods are playing an increasing role in discovery campaigns. This text emphasizes practical considerations for selecting and deploying core biophysical method, including but not limited to ITC, SPR, and both ligand-detected and protein-detected NMR. Topics covered include: Design considerations in biophysical-based lead screening Thermodynamic characterization of protein-compound interactions Characterizing targets and screening reagents with HDX-MS Microscale thermophoresis methods (MST) Screening with Weak Affinity Chromatography Methods to assess compound residence time 1D-NMR methods for hit identification Protein-based NMR methods for SAR development Industry case studies integrating multiple biophysical methods This text is ideal for academic investigators and industry scientists planning hit characterization campaigns or designing and optimizing screening strategies.
(source: Nielsen Book Data)9781119099482 20170731
Book
xiii, 290 pages, 32 unnumbered pages of plates : color illustrations, map ; 24 cm.
For more than one thousand years Arab medicine held sway in the ancient world, from the shores of Spain in the West to China, India and Sri Lanka (Ceylon) in the East. This book explores the impact of Greek (as well as Indian and Persian) medical heritage on the evolution of Arab medicine and pharmacology, investigating it from the perspective of materia medica - a reliable indication of the contribution of this medical legacy. Focusing on the main substances introduced and traded by the Arabs in the medieval Mediterranean - including Ambergris, camphor, musk, myrobalan, nutmeg, sandalwood and turmeric - the authors show how they enriched the existing inventory of drugs influenced by Galenic-Arab pharmacology. Further, they look at how these substances merged with the development and distribution of new technologies and industries that evolved in the Middle Ages such as textiles, paper, dyeing and tanning, and with the new trends, demands and fashions regarding spices, perfumes, ornaments (gemstones) and foodstuffs some of which can be found in our modern-day food basket.
(source: Nielsen Book Data)9780748697816 20170313
Green Library
Book
xx, 248 pages : color illustrations ; [ca. 23-29] cm.
  • Biosimilars for Drug Development. Regulatory Requirements on Biosimilars. System Biology in the Context of Biosimilars. Clinical Considerations on Biosimilars. Large Molecules Complete Molecular Confidence (CMC) Development Strategy. Immunogenicity. Interchangeability. Bridging a New Biologic to Its Reference Biologic. How to Account Covariate Effect to Show Non-Inferiority in Biosimilars. Novel Method in Inference of Equivalence in Biosimilars. Multiplicity Adjustment in Equivalence Using Two One-Sided Tests. Bayesian Methods in Biosimilar Studies.
  • (source: Nielsen Book Data)9781482231694 20171218
Biosimilars have the potential to change the way we think about, identify, and manage health problems. They are already impacting both clinical research and patient care, and this impact will only grow as our understanding and technologies improve. Written by a team of experienced specialists in clinical development, this book discusses various potential drug development strategies, the design and analysis of pharmacokinetics (PK) studies, and the design and analysis of efficacy studies.
(source: Nielsen Book Data)9781482231694 20171218
Book
online resource (19 pages) : color illustrations, charts
  • Background
  • Roadmap
  • The Cost Savings Potential of Biosimilars
  • An Evolving Market
  • Prior Cost Savings Estimates
  • The Need for Updated Cost Savings Estimates
  • Recent Literature on Biosimilar Cost Savings
  • Calculating an Updated Estimate of Biosimilar Cost Savings
  • Limitations of Our Cost Savings Estimate
  • Who Will Benefit from Biosimilar Cost Savings?
  • The Future of the U.S. Biosimilars Market
  • Is Policy Change Necessary?
  • Conclusion
  • Notes.
"The Biologics Price Competition and Innovation Act (BPCIA), enacted as part of the 2010 Patient Protection and Affordable Care Act (ACA), authorized the U.S. Food and Drug Administration (FDA) to create a new regulatory approval pathway for biosimilars, which are biologic drugs that are very similar to already approved "reference" biologics in terms of potency, safety, and efficacy, but are manufactured by different companies. In the seven years since the ACA, many drug manufacturers worked to push new biosimilars through development and FDA review. As of July 2017, there were three marketed biosimilars and two more that were approved by the FDA but not yet marketed. BPCIA's shorter, lower-cost biosimilar approval pathway was designed to introduce competition among biologic manufacturers. This Perspective estimates potential future savings from biosimilars in the United States, summarizes the experience to date with the first marketed biosimilar in the United States, and discusses key policy issues surrounding biosimilars. We estimate that biosimilars will reduce direct spending on biologic drugs by $54 billion from 2017 to 2026, or about 3 percent of total estimated biologic spending over the same period, with a range of $24 to $150 billion. While our estimate uses recent data and transparent assumptions, we caution that actual savings will hinge on industry and regulatory decisions as well as potential policy changes to strengthen the biosimilar market"--Publisher's description.
Medical Library (Lane)
Book
xiv, 596 pages : illustrations ; [ca. 23-29] cm
  • Chapter 1: Basic Concepts in Drug Targeting Chapter 2: Biological Targets: Identification, Selection and Validation Chapter 3: Emerging Therapeutic Targets for Diabetes Chapter 4: Prodrug Strategy: An Effective Tool in Drug Delivery and Targeting Chapter 5: Drug Targeting Strategies to CNS Disorders Chapter 6: Natural Polymers in Colon Targeting: Approaches and Future Perspectives Chapter 7: Lymphatic Drug Targeting Chapter 8: New Drug Targets and Drug Delivery Strategies for Various Ocular Disorders Chapter 9: Bone Target Drug Delivery Systems Chapter 10: Targeted Drug Delivery in Solid Tumours: An Overview and Novel Approaches for Therapy Chapter 11: Mitochondria as an Emerging Target for the Delivery of Small Therapeutic Molecules Chapter 12: Antisense Oligonucleotide-Mediated Target Specific Gene Silencing: Design, Delivery Strategies and Therapeutic Applications Chapter 13: Biodegradable Polymeric Carriers for Delivery of siRNA Chapter 14: Organic-Inorganic Nanocomposites for Biomedical Applications Chapter 15: Carbon Nanotube Induced Targeted Drug Delivery Chapter 16: Functionalized Cyclodextrin: A Versatile Supramolecular Systems for Drug Delivery Chapter 17: Nanopolymer Scaffolds as Novel Carriers for Cells and Drugs Chapter 18: Biotargets for Polyionic Glucan Derivatives and their Nano-Therapeutic Systems Chapter 19: Novel Carriers for Targeted Delivery of Herbal Medicines Chapter 20: Toxicological Concerns Related to Nanoscale Drug Delivery Systems.
  • (source: Nielsen Book Data)9781498730006 20171218
The advances in drug delivery systems over recent years have resulted in a large number of novel delivery systems with the potential to revolutionize the treatment and prevention of diseases. Bio-Targets and Drug Delivery Approaches is an easy-to-read book for students, researchers and pharmaceutical scientists providing a comprehensive introduction to the principles of advanced drug delivery and targeting their current applications and potential future developments.
(source: Nielsen Book Data)9781498730006 20171218
Book
1 online resource ( xv, 328 pages) : illustrations (some color).
  • Chapter 1 Medicinal Plants: Ethno-Uses to Biotechnology Era.- Chapter 2 How Plants Can Contribute to the Supply of Anti-Cancer Compounds.- Chapter 3 Cancer and Biotechnology: A Matchup that Should Never Slowdown.- Chapter 4 Plant Derived Compounds with Anti-Cancer Properties: From Folklore to Practice.- Chapter 5 Anticancer Drugs from Plants.- Chapter 6 Cambial Meristematic Cells: A Sustainable Platform for the Production of Plant-Derived Anti-Cancer Crugs.- Chapter 7 Family Fabaceae: A Boon for Cancer Therapy.- Chapter 8 Small Cells For Big Ideas: The Cytotoxic Podophyllotoxin And The Long Journey In Discovering Its Biosynthetic Pathway.- Chapter 9 Hairy Root Culture for the Production of Useful Secondary Metabolites.- Chapter 10 Edible Mushrooms and Their In Vitro Culture as a Source of Anticancer Compounds.- Chapter 11 Genomics and Artificial Intelligence Working Together in Drugs Discovery and Repositioning: The Advent of Adaptive Pharmacogenomics in Glioblastoma and Chronic Arterial Inflammation Therapies.- Chapter 12 A Multiscale Haemorheological Computer-based Model of Chronic Inflammation: an in-Depth Investigation of Erythrocytes-driven Flow Characteristics in Atheroma Development.
  • (source: Nielsen Book Data)9783319538792 20170821
This book discusses cancers and the resurgence of public interest in plant-based and herbal drugs. It also describes ways of obtaining anti-cancer drugs from plants and improving their production using biotechnological techniques. It presents methods such as cell culture, shoot and root culture, hairy root culture, purification of plant raw materials, genetic engineering, optimization of culture conditions as well as metabolic engineering with examples of successes like taxol, shikonin, ingenol mebutate and podophylotoxin. In addition, it describes the applications and limitations of large-scale production of anti-cancer compounds using biotechnological means. Lastly, it discusses future economical and eco-friendly strategies for obtaining anti-cancer compounds using biotechnology.
(source: Nielsen Book Data)9783319538792 20170821
ProQuest Ebook Central Access limited to 1 user
Book
ix, 806 pages : color illustrations, color maps ; 30 cm
This is the first botanically authoritative and practical illustrated identification guide to Chinese medicinal plants and drugs and their substitutes. It offers authoritative guidance on the identification of the herbal drugs themselves, and the plants from which they are sourced. Over the past 15 years, the authors have been collecting plant specimens throughout China, using verified species to create typical TCM reference drugs, prepared according to traditional methods. The herbal drugs included in this book are officially recognised from the Chinese materia medica (as defined in the Chinese Pharmacopoeia) and their selection has been based on those popular in international trade, as well as those recognised by the European Herbal and Traditional Medicine Practitioners Association, and those that are easily confused, substituted or adulterated with other plants.
(source: Nielsen Book Data)9781842463871 20170717
Science Library (Li and Ma)
Book
1 online resource (96 pages).
  • Introduction Networks and Pathways in Systems Pharmacology Time Varying Methods for Pathway and Sub-Pathway Analysis Identification of Differentially Expressed Pathways and Sub-Pathways.
  • (source: Nielsen Book Data)9783319538679 20180521
This work offers a guided walkthrough of one of the most promising research areas in modern life sciences, enabling a deeper understanding of involved concepts and methodologies via an interdisciplinary view, focusing on both well-established approaches and cutting-edge research. Highlighting what pathway analysis can offer to both the experimentalist and the modeler, the text opens with an introduction to a general methodology that outlines common workflows shared by several methods. This is followed by a review of pathway and sub-pathway based approaches for systems pharmacology. The work then presents an overview of pathway analysis methods developed to model the temporal aspects of drug- or disease-induced perturbations and extract relevant dynamic themes. The text concludes by discussing several state-of-the-art methods in pathway analysis, which address the important problem of identifying differentially expressed pathways and sub-pathways.
(source: Nielsen Book Data)9783319538679 20180521
Book
1 online resource ( viii, 87 pages.) :.
  • Introduction Networks and Pathways in Systems Pharmacology Time Varying Methods for Pathway and Sub-Pathway Analysis Identification of Differentially Expressed Pathways and Sub-Pathways.
  • (source: Nielsen Book Data)9783319538679 20180521
This work offers a guided walkthrough of one of the most promising research areas in modern life sciences, enabling a deeper understanding of involved concepts and methodologies via an interdisciplinary view, focusing on both well-established approaches and cutting-edge research. Highlighting what pathway analysis can offer to both the experimentalist and the modeler, the text opens with an introduction to a general methodology that outlines common workflows shared by several methods. This is followed by a review of pathway and sub-pathway based approaches for systems pharmacology. The work then presents an overview of pathway analysis methods developed to model the temporal aspects of drug- or disease-induced perturbations and extract relevant dynamic themes. The text concludes by discussing several state-of-the-art methods in pathway analysis, which address the important problem of identifying differentially expressed pathways and sub-pathways.
(source: Nielsen Book Data)9783319538679 20180521
ProQuest Ebook Central Access limited to 1 user
Book
1 online resource : text file, PDF
  • PART-A: INDUSTRIAL ASPECTS OF PHYTOMEDICINE Introduction to Phytomedicine Phytopharmacovigilance Phytopharmacoeconomics Phytopharmacoepidemiology Phytopharmacogenomics Ethics in Phytomedicine Herbosomes Nanophytomedicine Metabolomics and Phytomedicine Clinical Research in Ayurveda Excepients for Phytomedicine Certifications for Phytodrug Industry Dhsea Acts Related to Banned or Restricted Phyto Ingredients Comfrey Based Herbal Products Herbal Bioenhancers PART-B: BIOACTIVES FROM PHYTOMEDICINE Phytosteroids and Related Compounds Botany of Phytosteroids Containing Medicinal Plants Pharmacology of BETA-Sitosterol and Other Sterols Pharmacology of Disogenin and Related Compounds Steroidal Alkaloids Guggulsterones Phytoecdysteroids Botany of Withanolides Containing Medicinal Plants Pharmacology of Withaferin A Pharmacology of Withanolide A Pharmacology of Withanone Pharmacology of Withanolide D Miscellaneous Withanolides Sitoindosides Pyrrolizidine Alkaloids Phytocannabinoids Wild Cannabis Annexures (1-9) Related to Herbal Drug Registration Acronyms and Abbreviations Definitions Herbal Glossary.
  • (source: Nielsen Book Data)9781498773553 20171218
The term phytomedicine was coined by French physician Henri Leclerc in 1913. Till recently phytomedicine has remained in the background. But due to emerging challenges to the conventional pharmaceutical industry (cost effectiveness and potency of the drugs), phytomedicine has made a dramatic comeback. Phytomedicine has witnessed several changes and several new concepts have been introduced. Phytomedicine, although, a separate discipline, is strongly linked to Phytotherapy and Phytopharmacology. As the title suggests the book is an attempt to bridge the gap between fundamental and emerging concepts in this field of medicine. The book has been divided into two parts. Part A deals with core issues of the phyto-pharmaceutical drug industry. The book begins with an introductory chapter dealing with basic definitions with phytomedicine. Chapters 2-5 narrate emerging subjects such as Phytopharmacovigilance, Phytopharmacoeconomics, Phytopharmacoepidemiology and Phytopharmacogenomics. Chapter 6 discusses ethical issues in phytomedicine. Chapter 7 covers recent advances in drug delivery systems in phytomedicine whereas Chapter 8 is about application of nanotechnology in the field of phytomedicine. The further chapters cover metabolomics, regulatory and legal aspects of the phyto-pharmaceutical drug industry. The chapter on herbal bioavailability enhancing agents is the salient feature of Part-A. Part B is related to applied research in the field of phytomedicine. Experimental findings on phyto-bioactive agents such as withanolides, steroidal alkaloids, phytosteroids and phytocannabinoids have been elaborated. Nine annexures related to herbal drug registration are included.
(source: Nielsen Book Data)9781498773553 20171218